choppi continu walgreen firm
search answer shift market
page full analyst note
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim dec
price data apr
rate updat apr
currenc amount express
valuat growth profit
methodolog valu compani
walgreen one success retail oper
sinc found remain major player within
pharmaceut suppli chain mani decad firm
process approxim total prescript
fiscal make one largest retail pharmaci
acquisit europe-bas allianc boot firm
premier global retail powerhous
nevertheless believ walgreen face pressur oper
environ given rapidli grow price power pharmaci
custom walgreen deriv vast major prescript
revenu third-parti payer larg major pharmaci
benefit manag larg pbm abl aggreg enorm
amount claim volum leverag power price
walgreen tri off-set headwind drive volum
consolid firm recent receiv regulatori
approv acquisit half store fleet
solidifi largest retail pharmaci chain
acquisit increas volum geograph reach
also materi augment global gener purchas volum
walgreen also better-posit build prefer
pharmaci strategi strategi entail retail pharmaci
discount gener drug inventori becom prefer
pharmaci pbm retail network drive store foot traffic
approxim two third walgreen revenu deriv
sale prescript drug believ firm analog
mix sever discretionari retail entiti
walgreen manag look push sale front-stor
product order drive revenu profit opinion
demonstr weaker posit along pharmaceut suppli
chain walgreen tri off-set pressur retail
pharmaci oper environ cosmet groceri
household conveni good strategi also put
firm even direct competit vast array retail
sector profit outsiz return invest
capit hard come
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
walgreen one nation largest retail pharmaci
drugstor throughout unit state firm recent acquir half
locat push store count approxim
larg network store enabl firm reach signific portion
 popul provid excel brand recognit prescript
drug account two third sale balanc attribut
front-stor product groceri health beauti item
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
choppi continu walgreen firm
search answer shift ket
walgreen struggl cope rapidli chang
pharmaceut market pressur reimburs
massiv consolid increas competit
prescript volum firm aggress pursu
strategi becom anchor pharmaci mani
narrow pbm pharmaci network possibl order
becom prefer pharmaci walgreen discount
gener drug suppli profit taken hit
result quarter differ firm report
total gross margin compress basi point
adjust gross margin oper
compress basi point order backfil
lower level pharmaceut profit manag
tri drive
increas sale front-of-the-stor
continu drag same-stor sale
categori fall manag mention
ration number product sell product
discount dynam like contribut
front-end product sale either neg
margin posit last sever quarter trend
concern fall line long-term outlook
retail pharmaci reiter no-moat
rate fair valu estim
player within pharmaceut space
entiti better known resid retail
pharmaci combin dynam prime retail
personnel need essenti core product would lead
one believ firm posit consist
produc econom profit howev believ walgreen
face steep long-term headwind struggl
margin compress firm discount drug
inventori order drive store traffic tri
drive front-stor sale off-set profit pressur
result last sever quarter indic
strategi yet show inde preserv grow
profit walgreen perspect firm
long-term profit outlook remain uncertain see long-
term challeng ahead retail pharmaci
perspect signific consolid among major
pharmaci variou shift strategi away
core pharmaceut sale major retail chain
underscor tighten oper environ
valuat growth profit dec
fair valu estim walgreen
factor acquisit approxim rite aid
store walgreen acquir total number
store initi sought action allow
firm move larger store count also
particip sourc remain gener inventori
wbad partnership ad volum
lucr joint ventur lower gener cost given
circumst believ correct cours
action think firm like reap
value-cr synergi deal howev remain
cautiou firm success integr asset
network given underinvest natur
rite aid store asset overal action modestli
posit dcf valuat also believ firm
continu produc solid long-term valu gener
sourc joint ventur boast
express script member
perspect recent strateg partnership
walgreen close allow gain greater
distribut effici enhanc manufactur price
leverag ultim lead increas profit
next year forecast adjust prescript
increas moder driven firm continu recoveri
disput express script shift
demograph increas pharmaceut usag
offset dynam gener becom greater
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
face even price pressur drug benefit plan
payer addit assum secular trend
boost secular pharmaceut demand strong
initi believ firm front-stor strategi
fail boost nonprescript product sale averag
 growth scenario fair valu
estim decreas
obtain moat retail groceri conveni
good industri extrem tough endeavor given
dynam believ walgreen possess
econom moat confluenc price pressur
govern entiti greater competit mass
grocer
retail heavi depend
nonpharmaceut front-stor product profit
steadili push firm return invest capit
downward fact roic adjust oper leas
steadili fallen toward firm adjust weight averag
cost capit past five year
forese signific recoveri metric believ
return remain trajectori
off-set aforement headwind
walgreen sought enhanc supplier
purchas power acquir allianc boot major
retail distributor
partner amerisourcebergen
pharmaceut distributor purchas half rite
aid retail locat opportun gain distribut
effici enhanc manufactur price leverag
relationship posit walgreen
howev partnership direct respons
price pressur firm face larg payer
opinion walgreen need off-set price pressur
lower reimburs rate payer build
percentag prescript fill payer look
way hold overal cost employe benefit check
also project firm sale front-stor product
nonpharmaceut good grow line overal
growth mix assumpt give walgreen
five-year revenu compound-annual-growth-rate averag oper margin
rang explicit
scenario analysi take consider effect
custom supplier price negoti leverag
overal demand use pharmaceut product
growth rate front-stor product bull-cas
scenario factor less price profit pressur
due custom price demand increas supplier
price leverag addit factor acceler
growth front-stor product assum success
front-stor sale strategi scenario fair valu
estim increas
bear case assum recent recoveri
express script disput slow materi firm
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
supplier negoti power potenti gain better
manufactur price said total
convinc strateg move abl significantli
chang long-term trajectori firm abil
produc consist econom profit roic
posit influenc tactic believ
effici gain off-set price power drug
plan payer variabl consum discretionari
believ walgreen stabl moat trend even though
firm may possess competit advantag
consist produc econom profit believ
competit posit erod either
player along pharmaceut suppli chain
signific leverag walgreen believ
enough valu firm vast network retail
locat ensur stabl moat trend firm extens
retail footprint conveni locat throughout
prime
distribut channel solid variabl keep
econom moat stabl addit believ addit
around store acquir rite aid
expand geograph market reach area
littl presenc addit market share
help least stem profit pressur
recogn brand
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
owalgreen one largest retail pharmaci
approxim -base store post-
acquisit vast network give firm
abil reach consum give
excel scale conveni advantag
oth confluenc price pressur custom
greater competit mass grocer retail
heavi depend nonpharmaceut
product profit steadili push roic
opharmaceut spend grow solidli
next sever year given demograph shift
expans medic insur coverag
uninsur drive demand walgreen core back-
orec partnership potenti provid
improv result retail pharmaci
owalgreen contend payer custom base
signific price power thank power
posit major pbm
oth firm face increas direct competit
mass grocer retail believ
advantag reli conveni mild
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
walgreen oper decent level financi leverag
firm debt-to-ebitda ratio end
fiscal even though firm use signific
portion cash acquisit approxim
store believ firm need
issu new debt believ firm abl rebuild
cash balanc without problem sinc assum
debt deal
main risk face walgreen price pressur
prescript benefit payer retail custom supplier
pharmaceut product even though firm
recent sought strike partnership tone
player along drug suppli chain anoth contract
disput major pbm could caus contract
top- bottom-lin result effect
oligopoli firm retail pharmaci oper face
sizabl price pressur variabl even
heighten given focu mani drug plan payer
signific portion walgreen result depend
consum discretionari spend fluctuat
materi econom cycl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
major manag shakeup walgreen
calendar sever firm top execut
left pharmaci retail includ ceo greg wasson
sever oper misstep motiv departur
includ billion-dollar forecast error relat cost
sever pharmaceut product major contract
disput express script addit believ
manag decis execut tax invers
strategi caus mani key sharehold lose
confid firm strateg direct
stefano pessina firm major sharehold
ceo execut director sinc c-suit turnov
posit undoubtedli given iron grip
firm perspect everi aspect
oper strategi driven pessina larg
view mani current sharehold compet
retail given earlier turnaround allianc boot
busi believ extens success histori
oper europ largest retail pharmaci posit
walgreen futur strateg direct howev may
take pessina time acclim nuanc
 healthcar retail market
even leadership turnov believ certain
strateg move made previou manag team
ad posit walgreen long-term outlook
notabl allianc boot acquisit enhanc
firm overal retail oper built effici
distribut capabl addit firm
effect increas manufactur price negoti
power use combin demand
major retail firm integr partnership
along pharmaceut suppli chain move
particular help bolster distribut effici
supplier negoti leverag firm
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
rumor walgreen want follow familiar
buy-out playbook amerisourc may go along
feb wall street journal report walgreen
recent approach acquir
drug distributor remain equiti walgreen
alreadi transact would vertic integr
drug distribut retail pharmaci space within
 fall line strategi walgreen
current manag team execut europ built
allianc boot busi news still press
report believ rumor substanti
past year walgreen partner integr
signific portion oper asset equiti
amerisourc thu total merger seem like next
logic step retail pharmaci particularli given
desir firm leadership vertic integr
busi howev believ amerisourc may
share sentiment assign amerisourc
wide moat rate assign walgreen no-moat
rate believ vertic integr would benefit
walgreen amerisourc accordingli
premium fair valu estim leav
moat rate fair valu estim place given
offici announc either
inform regard moat valuat
analysi walgreen amerisourc pleas
refer recent report healthcar observ
right prescript no-moat retail pharmaci
market sell drug easier said done moati
pharma channel healthcar observ under-valued
disrupt pbm mco wholesal jan
amazon berkshir hathaway jpmorgan
announc jan trio form independ
healthcar compani help control healthcar cost
 -base employe could
potenti given capit clout three partner
believ certain investor underappreci
moati natur healthcar suppli chain
formid competit advantag insul
signific headwind tri break vertic along
chain dynam healthcar market
difficult navig specul amazon
berkshir jp disrupt space leverag
impress capit war chest busi expertis
caus valuat pbm mco drug wholesal
retail pharmaci fall materi believ
stock price creat
opportun investor acquir solid wide-moat firm
discount would highlight express script
cardin particularli good
exact oper structur products/servic
ultim mandat partnership yet
develop partnership tri
sizabl corpor busi without major
chang within healthcar marketplac capit
manag clout three partner undoubtedli
great howev core-compet healthcar
relat take signific time legitim
oper develop addit believ potenti
new partnership would lack scale size provid
effici price power par major
healthcar servic firm especi case given
local densiti necessari obtain decent provid price
sourc joint ventur among retail pharmaci
drug distributor pharmaci benefit manag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
combin number employe firm
close million initi may seem like give
partnership signific price power howev even
firm abl leverag entir million-person
employe base would pale comparison larg
healthcar servic firm equival small/mid-
tier insur estim combin number cover
live five major mco approxim
million live three larg pbm million
live respect thu price power new
partnership would garner significantli lower
healthcar servic firm built addit
mani employe trio base intern
hous independ oper like bring
total number one million potenti cover live
regul legal requir need effici
deliv healthcar extrem oner
absolut need consum safeti
would new entrant need compli variou feder
agenc claim regulatori jurisdict healthcar
servic product also countless state
municip foreign agenc licens regulatori
approv would take year new partnership fulli
compliant abl provid full-servic healthcar
servic employe administr work
wait period would also add signific time
regulatori approv process perspect amazon
berkshir jp new entrant healthcar
market would need partner one three larg
pbm one five larg mco order viabl
player within space
overview drug suppli chain would highlight
recent report sell drug easier said done
moati pharma channel analyz potenti
new competit within pharmaceut market
analysi wide moat exist space
walgreen report in-lin result volume-through-
discount strategi full jan
report first-quart result
fell line long-term outlook retail pharmaci
reiter fair valu estim no-
moat rate compani sought strategi drive
volum posit prefer pharmaci
mani major pharmaci benefit manag network
move significantli increas prescript volum
pharmaci sale also led lower gross margin
quarter gross margin fell basi point
off-set gross profit headwind firm sought
decreas sell gener administr cost
margin excel job front
quarter total sg percentag total sale
decreas basi point larg driven
retail pharmaci usa divis report
impress decreas sg cost margin
believ essenti trend
continu especi given firm preferred-pharmaci
strategi push gain share competit
even though preferred-pharmaci strategi increas
foot traffic walgreen plan yet produc
signific return same-stor sale firm front-of-
store product nonpharma product fell
quarter sixth consecut quarter trend key
compon manag plan drive sale higher-
margin health beauti product howev
skeptic whether firm compet
establish retail arena especi given
discrimin tast cosmet consum
anoth key compon walgreen volum strategi
relat acquisit half firm
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
continu integr acquir store
process expect end spring calendar
perspect firm probabl reap
value-cr synergi enhanc scale gain
materi share state lack
meaning presenc major concern need
revamp mani retail locat given lack
invest mani store experienc past
decad perspect may take least hand
year walgreen abl fulli benefit
view cvs/aetna merger oper posit
h/c servic thesi oct
oct sever media outlet report
talk acquir aetna report correct
believ larg oper posit
firm despit concern howev valuat
perspect continu see strong upsid
market underappreci well-posit pbm
busi view aetna overvalu
excess growth expect said
keep fair valu estim wide-moat rate
fair valu narrow moat rate
aetna intact review rate offici
announc deal receiv detail directli
either firm
posit neg potenti
vertic integr strategi opportun materi
touch almost everi aspect healthcar continuum
make new cvs/aetna servic firm one
power player within space scale leverag
supplier price advantag
capabl give potenti new entiti signific
advantag strategi fall line overal thesi
healthcar servic space believ firm
provid effici cost-sav servic thrive
long term especi case firm
signific scale combin cvs/aetna entiti
would level scale rival could match
nevertheless also drawback certain
pbm insur client may find tough partner
major rival certain aetna client may view
integr health insur product fix vendor
restrict addit specul regard
price pay acquir aetna would make deal
rich base stand-alone fair valu
note synergi futur strateg oper
option could add net present valu invest
said believ oper posit
larg outweigh neg potenti merger
initi take major posit neg
allow opportun continu
all-encompass healthcar strategi move
firm away moat retail pharmaci busi
give pbm integr product use offer
variou health insur option client allow
control signific portion spend cover
live across market strengthen
alreadi
formid advantag major pbm
aetna abl diversifi oper
strengthen long-term advantag combin
wide moat pbm also chang trajectori
aetna perform within healthcar space give
sharehold pathway gain econom profit
could gener stand-alone basi
combin cvs/aetna servic behemoth abl
enjoy increas supplier price advantag cost
leverag firm abl integr cull
data analyt underwrit member treatment
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
manag also enhanc abil
negoti price provid pharmaceut manufactur
retail pharmaci
aetna abl leverag minut clinic
asset within retail store lower cost effici
role term move member lower cost option
certain less intens medic procedur school/
sport physic vaccin check-up minor
neg client book may see integr model
neg given concern relat partner
major rival and/or restrict natur
integr suit servic insur pbm client
may view necess share critic
oper data strategi major rival
unten addit client may view
restrict natur locked-in retail pharmaci
asset formulari option less attract
offer vendor
difficulti combin two complex entiti could
pose major issu signific integr
member transit risk major healthcar servic
merger last decad run integr
issu comb back-offic sale client
servic function sever million individu
thousand client extrem difficult could
materi client defect integr fumbl
would point recent unitedhealth/catamaran express
scripts/medco cvs/caremark merger key
exampl dynam
price paid acquir aetna like rich
given stand-alone fair valu estim
current stock price synergi futur posit
oper strategi yield enough npv
materi sharehold valu destruct howev
believ opportun unlock great deal
valu given possibl new vertic integr
model includ end-custom asset
walgreen post quarter reimburs
pressur oper rite aid store mix oct
walgreen report result fell line long-
term outlook retail pharmaci reiter
fair valu no-moat rate firm strategi
gain prime posit prefer pharmaci list
express script pbm drove
excel prescript volum revenu growth total
prescript process quarter increas
lead directli increas pharmaci revenu
howev order obtain prime posit firm
materi discount gener inventori
price headwind pressur profit firm
compar year-ago-period gross oper
margin decreas basi point basi point
respect howev walgreen
abl lower central cost retail usa
divis basi point segment revenu
increas segment oper incom basi point
find develop highli posit
believ firm need optim -base
oper order off-set price pressur
continu face major pharmaci benefit manag
prefer pharmaci strategi increas foot traffic
walgreen manag hope turn
increas volum sale non-pharmaceut
product order fill profit gap howev dynam
yet develop same-stor sale front
store product non-pharma product fell
quarter -- fourth consecut quarter
trend manag note same-stor sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
health beauti oper increas
skeptic increas sale drive long-term
growth perspect firm discount
pharmaci non-pharmaci product order
drive foot traffic basket size strategi yet
increas
oper margin yet expand believ
critic firm scale asset cost basi order
preserv accept level sharehold return
key compon volum strategi relat
acquisit signific portion rite aid store
drama acquisit recent came end
walgreen acquir approxim half
network retail store outlet came two year
back forth feder trade commiss
signific anti-trust concern walgreen begun
process take ownership first state
process continu spring calendar
perspect firm like reap value-
creat synergi deal benefit
enhanc scale gain materi share state
lack meaning presenc manag also
state complet store integr
look close approxim lower-
perform legaci store retail portfolio
believ close under-perform retail locat
help manag optim oper resourc
lead better overal perform retail
transit pbm contract
remain favor long-term posit oct
oct announc offici move
pharmaci benefit manag contract express script
current agreement end
also transit pbm plan
manag relat function inhous servic
claim segment call ingeniorx move
larg expect upon initi analysi
leav moat fair valu rate intact anthem
plan leav moat rate
wide expect modestli increas fair valu
pbm new agreement fall line
aetna establish pbm
partner par insur size
howev interestingli also state also seek
win new pbm busi third-parti servic --
compet carved-out employ health plan client
begin
uncertain success
strategi believ firm current level prescript
volum make midtier pbm player best
like scale price power compet
major three pbm optum thu
believ dynam chose partner
rather execut activ intern said
opportun reap signific save
new contract manag state
like abl experi billion annual save
start given howev still believ
firm could achiev level save
establish new contract would
taken addit member transit risk
perspect like point strategi anthem
look diversifi oper along
becom third-parti pbm servic believ
develop strategi highlight moati critic
natur pbm busi
contract win gain materi level
claim add scale advantag howev
larg pbm contract signific portion servic
intern client usual carri lower-than-averag
level profit may benefit somewhat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
increas foot-traff store believ
impact minim one major posit firm
minut clinic clinic within retail store anthem
use asset part provid network
dynam highli benefici bring
promin provid asset move forward
factor increas claim volum modest profit
impact posit ancillari servic expect
slightli increas fair valu
contract develop also fall line outlook
believ desir third-parti
pbm valid thesi overal model
perspect remain advantag posit
long term billion prescript claim post-
posit favor benefit secular industri
tailwind firm client risk significantli lessen
client apart depart defens
make busi also believ
independ model major posit allow
healthcar servic behemoth offer flexibl
option client backdrop
reiter firm best idea believ stock
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end august
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
